Weekly Endocrinology Research Analysis
This week was dominated by major advances in metabolic therapeutics and mechanistic endocrinology: phase 3 trials of incretin-based poly-agonists (retatrutide) and dual agonists (mazdutide) demonstrated marked glycemic and weight benefits, while mechanistic work (irisin) provided human‑islet–level evidence for β‑cell rescue via an AMPK–mTORC1–S6K–ER Ca2+ axis. These findings accelerate the shift toward potent multimodal incretin therapies and nominate new β‑cell preservation pathways for transla
Summary
This week was dominated by major advances in metabolic therapeutics and mechanistic endocrinology: phase 3 trials of incretin-based poly-agonists (retatrutide) and dual agonists (mazdutide) demonstrated marked glycemic and weight benefits, while mechanistic work (irisin) provided human‑islet–level evidence for β‑cell rescue via an AMPK–mTORC1–S6K–ER Ca2+ axis. These findings accelerate the shift toward potent multimodal incretin therapies and nominate new β‑cell preservation pathways for translation. Clinical practice implications include broader adoption planning for powerful weight‑loss agents and prioritizing translational studies to test long‑term safety and cardiovascular/renal outcomes.
Selected Articles
1. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
In a 40-week, multicenter, double-blind phase 3 RCT (n=537), retatrutide monotherapy significantly improved HbA1c and produced substantial bodyweight reduction versus placebo in adults with T2D inadequately controlled by diet and exercise. Adverse events were consistent with GLP-1 agonist class effects, predominantly gastrointestinal.
Impact: Provides phase 3 evidence that triple-receptor (GIP/GLP-1/glucagon) agonism can deliver robust dual glycemic and weight benefits, representing a potential new class that could shift diabetes and obesity treatment paradigms.
Clinical Implications: If approved, retatrutide may become a potent monotherapy option for patients needing combined glycemic and weight reduction; clinicians should account for GI tolerability and await long-term safety and cardiovascular outcome data.
Key Findings
- 40-week randomized, double-blind, placebo-controlled phase 3 RCT across 48 sites randomized 537 adults to retatrutide 4, 9, or 12 mg or placebo.
- Retatrutide significantly improved glycemic control (HbA1c) and reduced body weight versus placebo.
- Adverse events were consistent with GLP-1 agonists, predominantly gastrointestinal in nature.
2. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
In a 60-week, double-blind, placebo-controlled phase 3 trial in Chinese adults with obesity (n=461 analyzed), once-weekly 9 mg mazdutide produced mean −16.65% weight loss versus −1.50% with placebo and 84.3% achieved ≥5% weight loss versus 33.1% with placebo. Gastrointestinal adverse events were common but mostly mild to moderate; discontinuation due to AEs was 2.9%.
Impact: Pivotal phase 3 evidence of large, clinically meaningful weight loss with a GLP‑1/glucagon dual agonist in an underrepresented (Chinese) population, supporting broadened global applicability of obesity pharmacotherapy.
Clinical Implications: Mazdutide may become an effective pharmacotherapy for moderate-to-severe obesity; clinicians should counsel patients regarding frequent GI effects and monitor cardiometabolic parameters, particularly when diabetes is coexisting.
Key Findings
- Mean percent weight change at week 60 was −16.65% with mazdutide versus −1.50% with placebo (between-group difference −15.15%; P<.001).
- ≥5% weight loss achieved by 84.3% in mazdutide group vs 33.1% in placebo.
- GI adverse events (vomiting 53.1%, nausea 46.9%, diarrhea 39.4%) were common but mostly mild-to-moderate; discontinuation due to AEs 2.9%.
3. The myokine irisin ameliorates the secretory dysfunction of pancreatic β cells in experimental and human type 2 diabetes.
Preclinical and ex vivo human-islet data show that irisin increases islet insulin content, glucose‑stimulated insulin secretion, and β‑cell proliferation in diabetic mice and restores insulin content and GSIS in human T2D islets. Mechanistically, under glucotoxic conditions irisin mobilizes ER Ca2+ via an AMPK–mTORC1–S6K–dependent pathway to rescue secretion coupling.
Impact: Presents mechanistic, cross-system evidence including human islets that a myokine can directly rescue β‑cell secretory dysfunction—opening a non‑incretin biological route to preserve β‑cell mass and function.
Clinical Implications: Irisin or agents targeting the AMPK–mTORC1–S6K–ER Ca2+ axis are candidates for development to preserve β‑cell functional mass in T2D; next steps include large-animal pharmacology and early-phase human trials to assess safety and efficacy.
Key Findings
- In HFD/STZ-diabetic mice, irisin increased islet insulin content, GSIS, and β-cell proliferation, improving glycemia.
- In human islets from T2D donors, irisin restored insulin content and glucose-stimulated insulin secretion.
- Under chronic high glucose, irisin enhanced ER Ca2+ mobilization via AMPK–mTORC1–S6K rather than CREB/AKT activation, rescuing secretion.